Darmmikrobiota und Silent Inflammation

Zusammenfassung

Bei vielen chronischen Erkrankungen werden Veränderungen der Darmmikrobiota als ätiologischer Mit-Faktor diskutiert. Doch was haben beispielsweise rheumatoide Arthritis und Diabetes mit dem Darm zu tun? Nach derzeitiger Erkenntnislage scheinen Barrierestörungen (Leaky Gut) mit daraus resultierenden, latenten chronischen Entzündungen der Schlüssel zu sein. Entsprechend wichtig sind die frühzeitige Erkennung und Behandlung solcher vom Darm ausgehenden „silent“ oder „low-grade inflammations“.

Abstract

For many chronic diseases alterations of the gut microbiota are discussed as one of the potential (main) etiologic factors. But what is the link between the gut and diseases like rheumatoid arthritis or diabetes? As known until yet, disruptions of the gut barrier function (leaky gut) with following latent chronic inflammations seems to be the key. Therefore an early diagnostic and therapy of this gut based “silent” or “low grade inflammations” is important.

Schlüsselwörter

Darmmikrobiota - Leaky Gut - Silent Inflammation - low-grade inflammation - Probiotika - Präbiotika

Key words

Gut microbiota - leaky gut - silent inflammations - low grade inflammations - probiotics - prebiotics

• Literatur

• 1 Atkinson W, Sheldon TA, Shaat N. et al. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomized controlled trial. Gut 2004; 53: 1459-1464
• 2 Bajaj JS, Heuman DM, Hylemon PB. et al. Randomized clinical trial: lactobacillus gg modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 2014; 39 (10) 1113-1125
• 3 Baothman OA, Zamzami MA, Taher I. et al. The role of Gut Microbiota in the development of obesity and Diabetes. Lipids Health Dis 2016; 15: 108 doi: 10.1186/s12944–016–0278–4
• 4 Brusca SB, Abramson SB, Scher JU. Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity. Curr Opin Rheumatol 2014; 26 (01) 101-107
• 5 Calder PC, Bosco N, Bourdet-Sicard R. et al. Health relevance of the modification of low grade inflammation in ageing (inflammageing) and the role of nutrition. Ageing Res Rev 2017; 40: 95-119
• 6 Di Cerbo A, Palmieri B, Aponte M. et al. Mechanisms and therapeutic effectiveness of lactobacilli. J Clin Pathol 2016; 69: 187-203
• 7 Gunasekeera V, Mendall MA, Chan D. et al. Treatment of Crohn’s Disease with an IgG4-Guided Exclusion Diet: Randomized Controlled Trial. Dig Dis Sci 2016; 61: 1148-1157
• 8 Hedin CR, McCarthy NE, Louis P. et al. Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn’s disease and their unaffected siblings. Gut 2014; 63: 1578-1586
• 9 Houser MC, Tansey MG. The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?. Parkinson’s Dis 2017; 3: 3 doi: 10.1038/s41531–016–0002–0
• 10 Nagpal R, Kumar M, Yadav AK. et al. Gut microbiota in health and disease: an overview focused on metabolic inflammation. Benef Microbes 2016; 7 (02) 181-194
• 11 Langhorst J, Boone J, Lauche R. et al. Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial. J Crohns Colitis 07/2016; 10 (07) 786-94 doi: 10.1093/ecco-jcc/jjw044
• 12 Langhorst J, Elsenbruch S, Koelzer J. et al. Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices. Am J Gastroenterol 2007; 102: 1-8
• 13 Langhorst J, Elsenbruch S, Mueller T. et al. Comparison of 4 Neutrophil-derived Proteins in Feces as Indicators of Disease Activity in Ulcerative Colitis. Inflamm Bowel Dis 2005; 11 (12) 1085-1091
• 14 Rüffer A, Eckert M, Krause D. et al. IgG-vermittelte Reaktionen auf Nahrungsmittel – physiologisch oder pathologisch?. umg 2013; 26: 93-94
• 15 Saad MJA, Santos A, Prada PO. Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance. Physiol 2016; 31: 283-293
• 16 Sanmiguel C, Gupta A, Mayer EA. Gut Microbiome and Obesity: A Plausible Explanation for Obesity. Curr Obes Rep 2015; 4 (02) 250-261
• 17 Strober W. The Impact of the Gut Microbiome on Mucosal Inflammation. Trends Immunol 2013; 34 (09) 423-430
• 18 Ukena SN, Singh A, Dringenberg U. et al. Probiotic Escherichia coli Nissle 1917 Inhibits Leaky Gut by Enhancing Mucosal Integrity. PLoS ONE 2007; 2 (12) e1308 doi: 10.1371/journal.pone.0001308
• 19 Vinolo MAR, Rodrigues HG, Nachbar RT. et al. Regulation of Inflammation by Short Chain Fatty Acids. Nutrients 2011; 3: 858-876